Search
-
Pandemic (H1N1) 2009 Influenza Update: Results from second clinical trial of GSK’s H1N1 adjuvanted vaccine confirm immune response and tolerability
Media
GSK announced results from a second clinical trial of its pandemic (H1N1) adjuvanted vaccine.
https://www.gsk.com/en-gb/media/press-releases/pandemic-h1n1-2009-influenza-update-results-from-second-clinical-trial-of-gsk-s-h1n1-adjuvanted-vaccine-confirm-immune-response-and-tolerability/
First published: 15 October 2009
-
Pandemic 2009 Influenza Update: Pandemrix™ data in an elderly population
Media
GlaxoSmithKline (GSK) today announced that this week, approximately half a million people will have received its pandemic H1N1 vaccine.
https://www.gsk.com/en-gb/media/press-releases/pandemic-2009-influenza-update-pandemrix-data-in-an-elderly-population/
First published: 27 October 2009
-
Medicines and Healthcare products Regulatory Agency authorises GSK’s Arexvy, the first respiratory syncytial virus (RSV) vaccine for older adults
Media
Authorisation will help protect adults 60 years of age and older in the UK from RSV disease for the first time
https://www.gsk.com/en-gb/media/press-releases/medicines-and-healthcare-products-regulatory-agency-authorises-gsk-s-arexvy-the-first-respiratory-syncytial-virus-rsv-vaccine-for-older-adults/
First published: 10 July 2023
-
US Department of Health and Human Services (HHS) purchases GSK’s A (H1N1) influenza antigen and proprietary adjuvant system
Media
GSK announced HHS has placed initial orders for H1N1 vaccine antigen and proprietary adjuvant system, AS03.
https://www.gsk.com/en-gb/media/press-releases/us-department-of-health-and-human-services-hhs-purchases-gsk-s-a-h1n1-influenza-antigen-and-proprietary-adjuvant-system/
First published: 21 May 2009
-
GSK presents new data for shingles candidate vaccine at IDWeek scientific conference
Media
GSK today announced new data for its shingles candidate vaccine ShingrixTM.
https://www.gsk.com/en-gb/media/press-releases/gsk-presents-new-data-for-shingles-candidate-vaccine-at-idweek-scientific-conference/
First published: 27 October 2016
-
Pandemic 2009 Influenza Update: Pandemrix™ data in children and adolescents from 3 to 17 years of age
Media
GlaxoSmithKline (GSK) today announced that over 40 million doses of its adjuvanted pandemic H1N1 vaccine have been distributed to countries.
https://www.gsk.com/en-gb/media/press-releases/pandemic-2009-influenza-update-pandemrix-data-in-children-and-adolescents-from-3-to-17-years-of-age/
First published: 22 November 2009
-
Synflorix™, GlaxoSmithKline’s pneumococcal vaccine, receives European authorisation
Media
Protection now possible against three pneumococcal strains not covered by currently available vaccine.
https://www.gsk.com/en-gb/media/press-releases/synflorix-glaxosmithkline-s-pneumococcal-vaccine-receives-european-authorisation/
First published: 31 March 2009
-
GSK signs agreement with the WHO to donate 50 million doses of pandemic H1N1 vaccine for distribution to developing countries
Media
GSK today announced that it has signed an agreement with WHO to donate 50 million doses of its influenza vaccine.
https://www.gsk.com/en-gb/media/press-releases/gsk-signs-agreement-with-the-who-to-donate-50-million-doses-of-pandemic-h1n1-vaccine-for-distribution-to-developing-countries/
First published: 09 November 2009
-
GSK Update: GSK’s Arepanrix™ H1N1 pandemic vaccine prequalified by the World Health Organization
Media
First prequalification for an H1N1 pandemic vaccine
https://www.gsk.com/en-gb/media/press-releases/gsk-update-gsk-s-arepanrix-h1n1-pandemic-vaccine-prequalified-by-the-world-health-organization/
First published: 30 November 2009
-
GSK receives FDA approval for expanded indication for FluLaval® Quadrivalent (Influenza Vaccine) for infants 6 months and older
Media
An approval from the US Food and Drug Administration’s (FDA) Center
https://www.gsk.com/en-gb/media/press-releases/gsk-receives-fda-approval-for-expanded-indication-for-flulaval-quadrivalent-influenza-vaccine-for-infants-6-months-and-older/
First published: 18 November 2016